JPMA To Suspend Novartis Membership Over Diovan Trials
This article was originally published in PharmAsia News
Executive Summary
The JPMA announced on Oct. 3 that it was processing the suspension of Novartis’s membership in the association after data falsification allegations regarding clinical trials of the company’s blood pressure drug Diovan.